Main Conference – Day 1Wednesday, 18 March 2026 - CET (Central European Time, GMT+01:00)

• Extracellular vesicles derived from microalgae (MEVs) are being developed as a universal delivery system for therapeutics, vaccines, and gene therapies.
• MEVs demonstrate high performance, safety, and flexibility in delivering diverse payloads, including mRNAs, siRNAs, oligos, plasmids, peptides, and proteins. They can be administered through various non-invasive routes, such as topical, ocular, oral, respiratory, intranasal, intramuscular, and intravenous, enabling delivery to hard-to-reach tissues while addressing limitations of existing delivery systems.
• MEV manufacturing is sustainable, simple, cost-effective, and GMP-ready. Production relies on environmentally friendly processes using light, fresh water, and minerals, ensuring a green and scalable approach.

• Splice Editors increase trans-splicing efficiency by leveraging CRISPR-Cas systems
• Splice Editor-enabled multi-kilobase edits unlock several key indications and pathogenic variants
• Splice Editing is a promising new modality for RNA editing

• Developing an innovative RNA splicing modulation platform to selectively target pseudo-exons, addressing genetic mutations that lead to aberrant splicing and disease progression.
• Leveraging advanced technologies to restore normal splicing patterns, enabling precise therapeutic interventions for a range of genetic disorders with high unmet medical needs.

Please contact the RNA Leaders Team (jade.osei-tutu@informa.com) if you are interested in presenting

Please contact the RNA Leaders Team (jade.osei-tutu@informa.com) if you are interested in presenting